JAK Inhibitors
On June 17, 2019, Aclaris Therapeutics Inc. issued a press release announcing positive results from a phase 2 clinical trial for men and women with androgenic alopecia. Trial Details From the press release: the trial results included 22 subjects of both men and women who applied a 0.46% solution of ATI-502 to their scalps twice…
According to its latest press release, Aclaris Therapeutics will be launching a phase 2 trial for the use of JAK inhibitors in androgenic alopecia (pattern hair loss) within the next few months. Here’s the line item from the press release about Aclaris’ trial in androgenic alopecia. AGA-201 Topical – a planned Phase 2 open-label clinical trial…
Hello everyone, and welcome to another edition of Weekly Thoughts. Things have been really busy in the hair world as of late, new companies are popping up all the time and companies that we have known about are finally making the announcements we want to hear. Lo and behold it’s almost been two months since…
Hello Everybody, Welcome to another edition of Weekly Thoughts. This weeks’s round-up includes new tidbits from Angela Christiano, Brian Urlacher’s hair transplant, Shiseido’s plethora of reseachers, and an Ultimate Guide update. Dr. Christiano Sheds Light on JAK Inhibitors Angela Christiano recently did an audio interview about her research on JAK inhibitors for hair growth. The…
The Holiday season is in full swing, and there is a lot to be happy about in the world of hair regeneration. For starters, Histogen and Replicel should both be available within about two years time. See previous post for expanded info. Also in this issue, I’m really excited about the new patents Angela Christiano…
Angela Christiano is up to it again, and the online hair world is very thankful. It was just a little over a year ago when the internet was ablaze with the news that Dr. Angela Christiano and her colleagues were studying the pharmaceutical drug ruxolitinib in cases of alopecia areata. Like tofacitinib, ruxolitinib is a…